Pharmadrug Inc. (TSE:PHRX) has released an update.
PharmaDrug Inc. has announced the appointment of Dr. David Kideckel, an experienced pharma industry executive, as the new Chairman of the Board, signaling a strategic move as the company advances its drug development programs. The company is poised for a ‘transformational’ year with progress in its PD-001 drug for oncology and infectious diseases, and advancements in biosynthetic pharmaceutical manufacturing through SecureDose. PharmaDrug’s subsidiary Sairiyo is moving forward with a Phase 1 clinical study in Australia for PD-001, leveraging the country’s R&D tax incentives.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.
